WESPAC Advisors LLC Has $876,000 Position in Johnson & Johnson (JNJ)

WESPAC Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 39.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,619 shares of the company’s stock after acquiring an additional 1,867 shares during the period. WESPAC Advisors LLC’s holdings in Johnson & Johnson were worth $876,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of JNJ. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter worth $177,000. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter worth $186,000. Finally, Intercontinental Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $200,000. 65.90% of the stock is owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) traded up $1.39 during trading hours on Thursday, hitting $141.06. 5,591,700 shares of the stock traded hands, compared to its average volume of 5,876,467. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $375,226.25, a P/E ratio of 19.56, a P/E/G ratio of 2.84 and a beta of 0.80. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

A number of analysts have recently weighed in on JNJ shares. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 1st. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective on the stock in a research note on Monday, October 30th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday, October 19th. Finally, UBS restated an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $144.59.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/07/wespac-advisors-llc-has-876000-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply